Sunovion Pharmaceuticals Inc., of Marlborough, Mass., said the FDA approved the supplemental NDA to expand the indication for its antiepileptic drug, Aptiom (eslicarbazepine acetate), to include treatment of partial-onset seizures in children and adolescents, ages 4 to 17.